Farmako specializes in the biosynthetic production of CBD in a genetically engineered tequila bacterium. The bacterium trademarked Zymomonas cannabinoidis, creates a cannabinoid factory that the company argues is faster and cheaper than synthesizing in yeast because it can produce cannabinoids for 900 hours without interruption where the yeast production does not happen continuously. In April 2019, Farmako received a three year supply contract from Zenabis for 36,000 kilograms of CBD.